Literature DB >> 28845895

Bone markers in polycystic ovary syndrome: A multicentre study.

Shilpa Lingaiah1, Laure Morin-Papunen1, Terhi Piltonen1, Johanna Puurunen1, Inger Sundström-Poromaa2, Elisabet Stener-Victorin3, Risto Bloigu4, Juha Risteli5, Juha S Tapanainen1,6.   

Abstract

OBJECTIVE: Hyperandrogenism, hyperinsulinaemia and obesity, known characteristics of polycystic ovary syndrome (PCOS), may influence bone mineral density and biochemical markers of bone turnover (BTMs) can provide a noninvasive assessment of bone turnover. To this end, the serum concentrations of BTMs and 25-hydroxyvitamin D (25OHD) were analysed in women with PCOS, and their possible associations with metabolic parameters of PCOS were determined. SUBJECTS AND METHODS: Bone formation markers procollagen type I amino-terminal propeptide (PINP) and osteocalcin (OC), and bone resorption marker carboxy-terminal cross-linking telopeptide of type I collagen (CTX), along with 25OHD, were measured in 298 women with PCOS and 194 healthy controls.
RESULTS: Serum levels of PINP (47.0 ± 20.2 vs 58.1 ± 28.6 μg/L, P < .001) and OC (18.2 ± 7.5 vs 20.6 ± 9.8 μg/L, P < .001) were decreased in women with PCOS compared with controls, whereas no significant differences were found in CTX and 25OHD levels. Age-stratified analyses suggested that PINP (50.5 ± 21.7 vs 68.2 ± 26.6 μg/L, P < .001) and OC levels (20.4 ± 7.6 vs 25.5 ± 9.6 μg/L, P < .001) were decreased only in the younger age group (≤30 years) women with PCOS compared with controls. The formation markers and resorption marker decreased with age in both study groups.
CONCLUSIONS: Bone formation markers were decreased in younger women with PCOS when compared with healthy women, which may affect bone mass in these women.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  biochemical markers of bone turnover; carboxy-terminal cross-linking telopeptide of type I collagen; osteocalcin; polycystic ovary syndrome; procollagen type I amino-terminal propeptide

Mesh:

Substances:

Year:  2017        PMID: 28845895     DOI: 10.1111/cen.13456

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  4 in total

Review 1.  The Role of Fibroblast Growth Factor 19 Subfamily in Different Populations Suffering From Osteoporosis.

Authors:  Xiawen Yu; Yue Xia; Jue Jia; Guoyue Yuan
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-28       Impact factor: 6.055

2.  Lean Women on Metformin and Oral Contraceptives for Polycystic Ovary Syndrome Demonstrate a Dehydrated Osteosarcopenic Phenotype: A Pilot Study.

Authors:  Charikleia Stefanaki; Flora Bacopoulou; Eleni Kandaraki; Dario Boschiero; Evanthia Diamandi-Kandarakis
Journal:  Nutrients       Date:  2019-09-02       Impact factor: 5.717

Review 3.  Androgens and Androgen Receptor Actions on Bone Health and Disease: From Androgen Deficiency to Androgen Therapy.

Authors:  Jia-Feng Chen; Pei-Wen Lin; Yi-Ru Tsai; Yi-Chien Yang; Hong-Yo Kang
Journal:  Cells       Date:  2019-10-25       Impact factor: 6.600

Review 4.  Oxidative Stress and Low-Grade Inflammation in Polycystic Ovary Syndrome: Controversies and New Insights.

Authors:  Antonio Mancini; Carmine Bruno; Edoardo Vergani; Claudia d'Abate; Elena Giacchi; Andrea Silvestrini
Journal:  Int J Mol Sci       Date:  2021-02-07       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.